Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

28 июля 2016 г. обновлено: Boehringer Ingelheim

LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations

The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by RECIST criteria in patients with advanced NSCLC Stage IIIB or IV whose tumors harbor activating mutations within exon 18 to exon 21 of the EGFR receptor. Patients progressing or relapsing after one prior cytotoxic chemotherapy regimen as well as chemotherapy naïve patients (only in stage 2) will be allowed to enter into the trial.

Обзор исследования

Статус

Завершенный

Условия

Вмешательство/лечение

Тип исследования

Интервенционный

Регистрация (Действительный)

129

Фаза

  • Фаза 2

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

  • Соединенные Штаты
    • California
      • Bakersfield, California, Соединенные Штаты
        • 1200.22.28 Boehringer Ingelheim Investigational Site
      • Beverly Hills, California, Соединенные Штаты
        • 1200.22.32 Boehringer Ingelheim Investigational Site
      • Mission Hills, California, Соединенные Штаты
        • 1200.22.4 Boehringer Ingelheim Investigational Site
      • Orange, California, Соединенные Штаты
        • 1200.22.16 Boehringer Ingelheim Investigational Site
    • Florida
      • Fort Lauderdale, Florida, Соединенные Штаты
        • 1200.22.19 Boehringer Ingelheim Investigational Site
      • North Miami Beach, Florida, Соединенные Штаты
        • 1200.22.29 Boehringer Ingelheim Investigational Site
    • Georgia
      • Atlanta, Georgia, Соединенные Штаты
        • 1200.22.10 Boehringer Ingelheim Investigational Site
    • Illinois
      • Chicago, Illinois, Соединенные Штаты
        • 1200.22.18 Boehringer Ingelheim Investigational Site
    • Maryland
      • Bethesda, Maryland, Соединенные Штаты
        • 1200.22.3 Boehringer Ingelheim Investigational Site
    • Massachusetts
      • Boston, Massachusetts, Соединенные Штаты
        • 1200.22.14 Boehringer Ingelheim Investigational Site
    • Michigan
      • Flint, Michigan, Соединенные Штаты
        • 1200.22.24 Boehringer Ingelheim Investigational Site
    • Minnesota
      • Minneapolis, Minnesota, Соединенные Штаты
        • 1200.22.5 Boehringer Ingelheim Investigational Site
    • New York
      • New York, New York, Соединенные Штаты
        • 1200.22.15 Boehringer Ingelheim Investigational Site
      • New York, New York, Соединенные Штаты
        • 1200.22.26 Boehringer Ingelheim Investigational Site
      • Rochester, New York, Соединенные Штаты
        • 1200.22.1 Boehringer Ingelheim Investigational Site
      • Syracuse, New York, Соединенные Штаты
        • 1200.22.27 Boehringer Ingelheim Investigational Site
      • Valhalla, New York, Соединенные Штаты
        • 1200.22.25 Boehringer Ingelheim Investigational Site
    • Ohio
      • Canton, Ohio, Соединенные Штаты
        • 1200.22.6 Boehringer Ingelheim Investigational Site
    • Pennsylvania
      • Wynnewood, Pennsylvania, Соединенные Штаты
        • 1200.22.7 Boehringer Ingelheim Investigational Site
    • South Carolina
      • Mt. Pleasant, South Carolina, Соединенные Штаты
        • 1200.22.22 Boehringer Ingelheim Investigational Site
    • Virginia
      • Fairfax, Virginia, Соединенные Штаты
        • 1200.22.31 Boehringer Ingelheim Investigational Site
    • Washington
      • Renton, Washington, Соединенные Штаты
        • 1200.22.40 Boehringer Ingelheim Investigational Site
      • Seattle, Washington, Соединенные Штаты
        • 1200.22.33 Boehringer Ingelheim Investigational Site
  • Тайвань
      • Taichung, Тайвань
        • 1200.22.88604 Taichung Veterans General Hospital
      • Taichung, Тайвань
        • 1200.22.88605 China Medical University Hospital
      • Tainan, Тайвань
        • 1200.22.88606 Boehringer Ingelheim Investigational Site
      • Taipei, Тайвань
        • 1200.22.88601 National Taiwan University Hospital
      • Taipei, Тайвань
        • 1200.22.88602 Veterans General Hospital
      • Taipei City, Тайвань
        • 1200.22.88607 Boehringer Ingelheim Investigational Site
      • Taoyuan, Тайвань
        • 1200.22.88603 Chang Gung Memorial Hosp-Linkou

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 18 лет до 99 лет (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion criteria:

  1. Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with pleural effusion) adenocarcinoma or Stage IV adenocarcinoma.
  2. Presence of activating mutation(s) in exon 18 to exon 21 of the EGFR-receptor confirmed by direct DNA sequencing of NSCLC tumor tissue.
  3. Progressive disease following a first line cytotoxic chemotherapy regimen or have recurrent disease after prior neoadjuvant or adjuvant chemotherapy. Patients who have not received first-line cytotoxic chemotherapy can be enrolled in stage 2 of the trial, if the criteria for entering stage 2 are met.
  4. Patients with at least one tumor lesion that can accurately be measured by computed tomography (CT) or magnetic resonance imaging (MRI) in at least one dimension with longest diameter to be recorded as 20 mm using conventional techniques or 10 mm with spiral CT scan.
  5. Male or female patient aged 18 years.
  6. Life expectancy of at least three (3) months.
  7. Written informed consents that is consistent with ICH-GCP guidelines.
  8. Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2.

Exclusion criteria:

  1. More than one (1) prior cytotoxic chemotherapy treatment regimen for relapsed or metastatic NSCLC.
  2. Chemo-, hormone- (other than Megace®) or immunotherapy within the past 4 weeks or within less than four half-lives of the previous drug prior to treatment with the trial drug and/or persistence of toxicities of prior anticancer therapies which are deemed to be clinically relevant.
  3. Previous treatment with erlotinib (Tarceva®), gefitinib (Iressa®) or any other EGFR inhibiting small molecule or antibody.
  4. Brain metastases, which are symptomatic; patients with treated, asymptomatic brain metastases are eligible with stable brain disease for at least four (4) weeks without the requirement for steroids or anti-epileptic therapy.
  5. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohns disease, malabsorption, or CTCAE Grade >2 diarrhea of any etiology at baseline.
  6. Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
  7. Other malignancies diagnosed within the past five (5) years (other than non-melanomatous skin cancer and in situ cervical cancer).
  8. Radiotherapy within the past 2 weeks prior to treatment with the trial drug.
  9. Patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents).
  10. Patients with known HIV, active hepatitis B or active hepatitis C.
  11. Known or suspected active drug or alcohol abuse.
  12. Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial.
  13. Pregnancy or breast feeding.
  14. Patient unable to comply with the protocol.
  15. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA) functional classification of 3.
  16. Cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram.
  17. QTc interval greater than 0.47 second.
  18. Prior treatment with anthracyclines with a cumulative dose of doxorubicin (or equivalent) greater than 400 mg/m2.
  19. Absolute neutrophil count (ANC) less than 1500/mm3.
  20. Platelet count less than 100 000 /mm3.
  21. Bilirubin greater than 1.5 mg / dl (greater than 26 micromol / L, SI unit equivalent).
  22. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal).
  23. Serum creatinine greater than 1.5 times of the upper normal limit or calculated/measured creatinine clearance equal or less than 45 ml / min.
  24. Patients with known pre-existing interstitial lung disease

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Н/Д
  • Интервенционная модель: Одногрупповое задание
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: BIBW 2992
Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs. After protocol amendment 2 (17 Dec 2008), the starting dose of BIBW 2992 was reduced to a medium dose, with 2 possible dose reductions if needed after discontinuation due to drug-related AEs.
Лекарство: BIBW 2992
This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Objective Response (OR) as Determined by RECIST 1.0
Временное ограничение: Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.
Objective response (OR) was assessed for all treated patients by independent review as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. OR included complete response (CR) and partial response (PR), where CR or PR must have been confirmed by a subsequent response in ≥28 days.
Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Clinical Benefit as Determined by RECIST 1.0
Временное ограничение: Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.
Clinical benefit was evaluated according to RECIST 1.0 by independent review assessment. Patients whose best RECIST 1.0 assessment was stable disease (SD), partial response (PR), or complete response (CR) were considered to have derived a clinical benefit from treatment.
Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.
Duration of Clinical Benefit
Временное ограничение: Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.
Duration of clinical benefit (disease control) as per independent review was defined as the time from the start of treatment to the time of progression or death (whichever occurred first), among patients with evidence of SD, PR or CR.
Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.
Duration of Objective Response
Временное ограничение: Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.
Duration of objective response (OR) was measured from the time the criteria for CR or PR (whichever was documented first) were first met until the first date that progressive disease or death (or date of censoring for PFS) was objectively documented as per independent review.
Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.
Time to Objective Response
Временное ограничение: Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.

Time to objective response was defined as the number of days from the start of treatment to the first recorded objective response. Patients who did not experience objective response during the study were censored at the time of treatment discontinuation.

The results are provided as the percentage of participants for this Outcome Measure.
Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.
Progression-free Survival
Временное ограничение: Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.
Progression-free survival (PFS) as per independent review was defined as the duration of time from the start of treatment until the day of objective tumor progression was confirmed by tumor imaging (Progressive Disease according to RECIST 1.0) or death, whichever came first. Patients with unknown progression status or unknown date of progression were reviewed on a case-by-case basis. Patients known to be alive without progression at the end of the trial or the last follow-up visit were censored at the date of the last imaging when the patient was known to be alive and progression-free. Medians are calculated from the Kaplan-Meier estimates and 95% confidence intervals, using Greenwood's standard error estimate.
Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.
Overall Survival Time
Временное ограничение: Start of treatment to time to all death, up to 93 months
Overall survival time (OS) was also evaluated and was defined as the duration of time from start of treatment to time of death up to 93 months, regardless of the cause of death. Medians are calculated from the Kaplan-Meier estimates and 95% confidence intervals, using Greenwood's standard error estimate.
Start of treatment to time to all death, up to 93 months
Cpre,ss,29
Временное ограничение: -0:05h (pre-dose) on Day 29
Predose concentration of the analyte in plasma at steady state immediately before administration of the 29th dose (Cpre,ss,29).
-0:05h (pre-dose) on Day 29
Safety of BIBW 2992 as Indicated by Incidence of Specified Adverse Events.
Временное ограничение: First administration of trial medication until 28 days after last administration of trial medication, up to 93 months.
Safety of afatinib as indicated by incidence of specified adverse events: skin reactions (a preferred term of the system organ class: Skin and subcutaneous tissue disorders) and gastrointestinal (GI) (a system organ class).
First administration of trial medication until 28 days after last administration of trial medication, up to 93 months.
Safety of BIBW 2992 as Indicated by Intensity and Incidence of Worst Adverse Events Graded According to NCI CTCAE Version 3.0
Временное ограничение: First administration of trial medication until 28 days after last administration of trial medication, up to 93 months.
Safety of afatinib as indicated by intensity and incidence of worst adverse events graded according to National Cancer Institute (NCI) Common terminology criteria for adverse events (CTCAE) Version 3.0 (R04-0474).
First administration of trial medication until 28 days after last administration of trial medication, up to 93 months.

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Boehringer Ingelheim

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Общие публикации

Полезные ссылки

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования

1 августа 2007 г.

Первичное завершение (Действительный)

1 февраля 2010 г.

Завершение исследования (Действительный)

1 августа 2015 г.

Даты регистрации исследования

Первый отправленный

3 сентября 2007 г.

Впервые представлено, что соответствует критериям контроля качества

3 сентября 2007 г.

Первый опубликованный (Оценивать)

5 сентября 2007 г.

Обновления учебных записей

Последнее опубликованное обновление (Оценивать)

16 сентября 2016 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

28 июля 2016 г.

Последняя проверка

1 июля 2016 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • 1200.22

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Клинические исследования BIBW 2992

Искать похожие исследования

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

CROs by country

CROs in Australia

Заболевания

Редкие заболевания

Медикаментозные вмешательства

Пищевые добавки

Спонсор / Соавторы

Места

Подписаться